Technologies Available For Licensing

Damien Holzapfel          8,126,922          Issue Date 02/28/2012

CALENDAR SYSTEM

Abstract

A calendar system displays event data via an electronic calendar form that is accessible over a network by a user of a client computer.  The system stores event data for multiple events and selectively displays event data based on whether a calendar access request is received from a guest user or an authenticated user.  The system displays event data via a default calendar to guest users and displays event data via a customized calendar to authenticated users.  The default calendar displays event data for related events based on a contextual relationship that is derived by examining event data for each the multiple events to determine a position separation and/or a frequency of a user supplied keyword in the event data.  The customized calendar displays events based on contextual relationships and based on the viewing history of the user and other input data from user.

Robert Kizer          8,231,586          Issue Date 07/31/2012

CEREBROSPINAL FLUID COLLECTION TUBES AND METHODS

Abstract

A cerebrospinal fluid ("CSF") collection tube includes a bottom end portion and a tubular sidewall portion.  The tubular sidewall portion has a first end and a second end, the first end being sealed to the bottom end portion and the second end defining an open end portion of the CSF collection tube.  The CSF collection tube further includes a filament element that is attached to an interior surface of the tubular sidewall portion and projects through the open end portion of the CSF collection tube.  The CSF collection tube may further include a removable cap.

Alekha K. Dash         8,242,165          Issue Date 08/14/2012

MUCOADHESIVE NANOPARTICLES FOR CANCER TREATMENT

Abstract

The present invention relates to a pharmaceutical composition which includes nanoparticles.  The nanoparticles include a glyceryl monooleate or monolinoleate (or other mono fatty acid ester); a chitosan; and a cancer therapeutic agent, such as gemcitabine, taxanes, and hydrophobic cancer therapeutic agents.  Also disclosed are methods for preparing such nanoparticles and pharmaceutical compositions, as well as methods for treating breast, pancreatic, colon, prostate, and other cancers by parenterally, intravenously, or otherwise administering such nanoparticles and pharmaceutical compositions.

Nancy Jo Dohse Hanson          7,045,291          Issue Date 05/16/2006

MULTIPLEX PCR FOR THE DETECTION OF AMPC BETA-LACTAMASE GENES

Abstract

Oliognucleotide primers are provided that are specific for nucleic acid characteristic of certain AmpC beta-lactamases.  The primers can be employed in methods to detect the presence or absence of an AmpC beta-lactamase gene in samples, and to identify nucleic acid characteristic of AmpC beta-lactamase genes in samples, particularly, in clinical isolates of Gram-negative bacteria.

Nancy Hanson          7,521,547          Issue Date 04/21/2009

MULTIPLEX PCR FOR THE DETECTION OF AMPC BETA-LACTAMASE GENES

Abstract

Oliognucleotide primers are provided that are specific for nucleic acid characteristic of certain AmpC beta-lactamases.  The primers can be employed in methods to detect the presence or absence of an AmpC beta-lactamase gene in samples, and to identify nucleic acid characteristic of AmpC beta-lactamase genes in samples, particularly, in clinical isolates of Gram-negative bacteria.

Christopher J. Destache          8,846,096          Issue Date 09/30/2014

NANOPARTICLES AND METHODS OF USE

Abstract

Provided herein are nanoparticles and methods for using nanoparticles.  The nanoparticles include at least three antiretroviral agents.  When introduced to cells the nanoparticles cause an increase in the intracellular concentration of the antiretroviral agents to a level that is at least the IC50 against HIV-1 or HIV-2.  This concentration may be maintained for at least 21 days after the cells are contacted with the nanoparticle.  When administered to a subject the nanoparticles cause the concentration of the antiretroviral agents to increase to at least 100 ng/ml in the serum of the subject, at least 0.5 .mu.g/gram tissue in an organ of the subject, or a combination thereof.  Such a concentration may be maintained for at least 21 days after the administration.

Chris Destache          PCT/US2013/052829

POLYMERIC NANOPARTICLES IN A THERMOSENSITIVE GEL FOR COITAL-INDEPENDENT VAGINAL PROPHYLAXIS OF HIV

Abstract

An antiretroviral composition that gels upon heating and can be administered prophylactically prior to exposure to a retrovirus following sexual intercourse, and methods of using the same.

Gary Guishan Xiao          8,841,269          Issue Date 09/23/2014

POLYNUCLEOTIDES FOR USE IN TREATING AND DIAGNOSING CANCERS

Abstract

The present invention provides methods for increasing sensitivity of cancer cells to an antiestrogen agent, such as a selective estrogen receptor modulator (SERM).  The methods include administering to the subject a polynucleotide in an amount effective to increase the antiestrogen agent sensitivity of the cancer cells.  The cancer cells may be estrogen receptor positive, such as ER-a66 positive or ER-a36 positive, prior to the administering.  Also provided are methods for decreasing the amount of estrogen receptor present in a cancer cell, methods for determining whether antiestrogen agent sensitivity of cancer cells in a subject can be increased, methods for diagnosing whether a subject has, or is at risk for developing, cancer, and methods for identifying an agent that increases the amount of let-7 miRNA in a cell.

Nancy D. Hanson          6,242,223          Issue Date 06/05/2001

PRIMERS FOR USE IN DETECTING BETA-LACTAMASES

Abstract

Oliognucleotide primers are provided that are specific for nucleic acid characteristic of certain beta-lactamases.  The primers can be employed in methods to identify nucleic acid characteristic of family-specific beta-lactamase enzymes in samples, and particularly, in clinical isolates of Gram-negative bacteria.

Nancy D. Hanson          6,893,846          Issue Date 05/17/2005

PRIMERS FOR USE IN DETECTING BETA-LACTAMASES

Abstract

Oliognucleotide primers are provided that are specific for nucleic acid characteristic of certain beta-lactamases.  The primers can be employed in methods to identify nucleic acid characteristic of family-specific beta-lactamase enzymes in samples, and particularly, in clinical isolates of Gram-negative bacteria.

Nancy D. Hanson         6,905,848          Issue Date 06/15/2005

PRIMERS FOR USE IN DETECTING BETA-LACTAMASES

Abstract

Oliognucleotide primers are provided that are specific for nucleic acid characteristic of certain beta-lactamases.  The primers can be employed in methods to identify nucleic acid characteristic of family-specific beta-lactamase enzymes in samples, and particularly, in clinical isolates of Gram-negative bacteria.

Nancy D. Hanson          7,476,520         Issue Date 01/13/2009

PRIMERS FOR USE IN DETECTING BETA-LACTAMASES

Abstract

Oliognucleotide primers are provided that are specific for nucleic acid characteristic of certain beta-lactamases.  The primers can be employed in methods to identify nucleic acid characteristic of family-specific beta-lactamase enzymes in samples, and particularly, in clinical isolates of Gram-negative bacteria.

Ashfaque Hossain          8,062,845          Issue Date 11/22/2011

RAPID NUCLEIC ACID ISOLATION METHOD AND COMPOSITIONS

Abstract

A method of isolating RNA from a biological specimen is provided, whereby a biological specimen is contacted with an admixture of (i) a mono-phasic solution of phenol and guanidine isothiocyanate and (ii) a lysis buffer under conditions and for a time appropriate to form a homogenate.  Next, the homogenate is admixed with a water-immiscible organic solvent under conditions and for a time appropriate to form an aqueous phase and an organic phase.  The aqueous phase is then contacted with a C1-C4 lower alcohol under conditions and for a time to form a precipitated RNA.  The precipitated RNA is then recovered by centrifugation and decanting of the aqueous phase.  The method can also be used to isolate total RNA.  In an alternative embodiment, the biological sample is contacted with (i) a lysis buffer, and (ii) a mono-phasic solution of phenol and guanidine isothiocyanate under conditions and for a time appropriate to form a homogenate.  The remaining steps of this embodiment are the same as above.

Kristina Simeone          PCT/US2013/045353

SEIZURE THERAPY

Abstract

Method and a composition are utilized to affect mitrochondrial functions on a seizure-genic brain region.

Charles J. Filipi          5,813,976          Issue Date 09/29/1998

STABILIZING INSTRUMENTATION FOR THE PERFORMING OF ENDOSCOPIC SURGICAL PROCEDURES

Abstract

Apparatus and methods are disclosed for percutaneously providing a stabilized platform for performing endoscopic surgery.  The disclosed instrumentation includes an endoscope, a fixation catheter, a loop suture, and a rigid mount.  A loop end of the loop suture is inserted into the gastrointestinal lumen through the fixation catheter and encompasses the endoscope positioned within the gastrointestinal lumen.  The thread end of the loop suture remains external of the patient and is tautly connected to the rigid mount to provide the desired stability to the endoscope for the performance of an endo-surgical operation.  Distal to the stabilizing assembly, the endoscope has articulated joints for positioning the distal end of the endoscope in close proximity to the surgical site, and includes manipulator arms which extend beyond the distal face of the endoscope to facilitate access to the surgical site.

Roger D. Reidelberger          8,977,517          Issue Date 03/10/2015

SYSTEM AND METHODS FOR EVALUATING EFFICACY OF APPETITE-AFFECTING DRUGS

Abstract

System and methods to evaluate and administer drugs.  The present invention instantaneously identifies the effects that drugs, including appetite-affecting agents, have on animals.  Data is collected automatically and analyzed and further organized to identify feeding patterns and the effect an appetite-affecting agent has on those feeding patterns.  The present invention includes a system for data management, including a program with a data acquisition phase and a data analyzing phase to determine the feeding patterns of animals to aid in the evaluation of appetite-affecting drug efficacy.